title: Prognostic value of (18)F-FDG PET/CT metabolic parameters in metastatic differentiated thyroid cancers.
abstract: OBJECTIVE
  To evaluate the prognostic value of F-fluorodeoxyglucose positron emission tomography (FDG PET) with quantitative analysis using metabolic parameters in metastatic differentiated thyroid cancer (DTC).
  
  
  METHODS
  The FDG-PET scans of 37 patients with metastatic DTC were studied retrospectively. The number of FDG-avid lesions, the SUVmax, the SULpeak of the lesion with the highest FDG uptake, the overall metabolic tumor volume (MTV), and the total lesion glycolysis (TLG) were measured. Curves of progression-free survival (Kaplan-Meier) and Cox univariate and multivariate analyses determined the prognostic factors for survival.
  
  
  RESULTS
  Progression-free survival was better in patients with less than 10 FDG-avid lesions (P = 0.0089), the SUVmax less than 10 (P = 0.0026), the SULpeak less than 5 (P = 0.0004), and the TLG less than 154 (P = 0.0110).Cox analyses showed that only the result of the PET scan was predictive of survival (age, TNM stage, histology, and the I whole body radioiodine scan were not associated with prognosis). In the univariate analysis, prognostic factors for progression-free survival and overall survival were the SUVmax (P = 0.004; P = 0.018), the SULpeak (P = 0.001; P = 0.017), and the TLG (P = 0.014; P = 0.012). The number of FDG-avid lesions was significantly associated with progression-free survival (P = 0.012), but not the MTV. In the multivariate analysis, the number of FDG-avid lesions and the SULpeak were independent prognostic factors.
  
  
  CONCLUSIONS
  FDG PET using metabolic parameters is a prognostic factor in metastatic DTC. It could improve the therapeutic management and follow-up of patients.
authors.affiliation: From the *Service de Médecine Nucléaire, Institut Jean Godinot, Reims; †Unité thyroïde, Institut Jean Godinot, Reims; ‡Unité de Biostatistiques et Qualité de vie, Centre Georges-François Leclerc, Dijon; and §Service de Radiophysique, Institut Jean Godinot, Reims, France.
authors.forename: Soizic
authors.initials: S
authors.lastname: Masson-Deshayes
authors.forename: Claire
authors.initials: C
authors.lastname: Schvartz
authors.forename: Cécile
authors.initials: C
authors.lastname: Dalban
authors.forename: Sofiane
authors.initials: S
authors.lastname: Guendouzen
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Pochart
authors.forename: Audrey
authors.initials: A
authors.lastname: Dalac
authors.forename: Sandrine
authors.initials: S
authors.lastname: Fieffe
authors.forename: Claire
authors.initials: C
authors.lastname: Bruna-Muraille
authors.forename: Tienhan Sandrine
authors.initials: TS
authors.lastname: Dabakuyo-Yonli
authors.forename: Dimitri
authors.initials: D
authors.lastname: Papathanassiou
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D009362:Neoplasm Metastasis; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D014057:Tomography, X-Ray Computed; D047368:Tumor Burden; D055815:Young Adult
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18